SVB Securities Sticks to Its Buy Rating for AC Immune SA (ACIU)

In a report issued on August 1, Marc Goodman from SVB Securities maintained a Buy rating on AC Immune SA (ACIUResearch Report), with a price target of $10.00. The company’s shares closed last Tuesday at $3.27, close to its 52-week low of $2.06.

According to TipRanks.com, Goodman is a 1-star analyst with an average return of -0.4% and a 43.5% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Opthea Limited Sponsored ADR, and Amylyx Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AC Immune SA with a $13.00 average price target, which is a 301.2% upside from current levels. In a report issued on July 29, H.C. Wainwright also reiterated a Buy rating on the stock with a $16.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

AC Immune SA’s market cap is currently $268.2M and has a P/E ratio of -3.19.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Read More on ACIU:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More